XRTX — XORTX Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1729214 ·
Last close
$2.00
Market Cap
$3.63M
52W High
$2.72
52W Low
$1.88
ADV30
11,780
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -823,297 | -808,472 | 2,144,791 | 250,275 | 860,988 |
| Dec 2025 | 0 | — | -686,416 | -590,462 | 2,683,530 | 864,514 | 599,071 |
| Sep 2025 | 0 | — | -716,197 | -649,469 | 2,811,078 | 1,193,915 | 837,408 |
| Jun 2025 | 0 | — | -889,945 | -717,700 | 2,742,018 | 1,063,477 | 711,455 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-2,626,355
Investing CF
$-299,483
Financing CF
$1,255,768
CapEx
$-55,626
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.11
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-24,633,029
Inventory
—
Receivables
$64,633
ST Investments
—
EBIT TTM
$-3,115,855
Pretax Income TTM
$-2,766,103
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -3,256,014 | -2,656,304 | 2,683,530 | 599,071 | — | -2,768,723 |
| Dec 2024 | 0 | -4,118,319 | -3,313,346 | 4,094,527 | 757,990 | — | -3,678,648 |
| Dec 2023 | 0 | -6,045,986 | -2,158,065 | 5,467,964 | 825,938 | — | -6,583,165 |
| Dec 2022 | 0 | -10,290,606 | -7,718,882 | 12,374,026 | 5,377,215 | — | -8,165,959 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.80
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RDHL | RedHill Biopharma Ltd. | $3.68M | $0.61 | — |
| GOVX | GeoVax Labs, Inc. | $3.58M | $0.69 | — |
| MBIO | MUSTANG BIO, INC. | $3.71M | $0.55 | — |
| SXTP | 60 DEGREES PHARMACEUTICALS, INC. | $3.80M | $1.08 | — |
| SPRC | SciSparc Ltd. | $3.82M | $6.66 | — |
News headlines (Yahoo Finance, 1h cache)
XORTX Announces Director Resignation
2026-07-31 21:00 · Yahoo
XORTX Appoints New Director
2026-07-29 11:00 · Yahoo
XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO
2026-06-15 11:00 · Yahoo
XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange
2026-06-12 21:00 · Yahoo
XORTX Announces Closing of US$5 Million Public Offering
2026-05-19 11:00 · Yahoo
E.F. Hutton & Co. Serves as Exclusive Placement Agent on XORTX Therapeutics Inc. $5 Million Public Offering
2026-05-18 15:20 · Yahoo
XORTX Announces US$5 Million Public Offering
2026-05-14 11:00 · Yahoo
XORTX Meets Nasdaq Continued Listing Requirements
2026-04-21 11:00 · Yahoo
XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset
2026-04-13 21:00 · Yahoo
XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems
2026-02-04 23:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.